ISLAND PHARMACEUTICALS ORD
Island Pharmaceuticals Raises $9m to Fund Clinical Development as FDA Approves Galidesivir Pathway
Island Pharmaceuticals (ASX: ILA) secures FDA Animal Rule path for galidesivir and $9m funding to fast-track two-stage trials and US govt procurement potential.
Island Pharmaceuticals and Texas Biomed to Conduct Non-Human Primate Studies Using Antiviral Drug Galidesivir
Island Pharmaceuticals (ASX: ILA) has secured a master service agreement with Texas Biomedical Research Institute to support the development of lead antiviral molecule galidesivir.
Island Pharmaceuticals Joins Medical Countermeasures Coalition to Advance Galidesivir Against High-Priority Virus Threats
Island Pharmaceuticals (ASX: ILA) has been granted membership into the US-based Medical Countermeasures Coalition, an important milestone in its strategy to advance lead candidate galidesivir as a critical countermeasure against high-priority virus threats.
Island Pharmaceuticals Employs FDA Animal Rule in Development of Galidesivir to Counter Deadly Marburg Virus
Island Pharmaceuticals (ASX: ILA) has been granted an opportunity to advance approval of its lead candidate Galidesivir under the US Food and Drug Administration’s Animal Rule.